BioCentury | Oct 29, 2020
Product Development

Vowing transparency at interim COVID-19 vaccine readout, Moderna expects ‘dialogue’ with FDA about unblinding study

Contrasting comments from Pfizer management on Tuesday, Moderna promised full transparency with regard to interim results from its Phase III COVE study of COVID-19 vaccine mRNA-1273. The company pledged to report either a positive or...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

A $310 million crossover round will enable Chinese in-licensing play LianBio to “cast a wide net” as it looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury. Perceptive Advisors seeded,...
BioCentury | Oct 28, 2020
Deals

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

With $56 million in fresh funding from a crossover syndicate, newly launched Longboard will develop three neuroscience programs spun out from Arena that share familiar targets with therapies previously developed by the parent company. The...
BioCentury | Oct 28, 2020
Deals

Supply constraints loom as Regeneron reports positive data on COVID-19 mAb

Days before FDA is expected to decide about their emergency use authorization requests, Regeneron released new data confirming the efficacy of its COVID-19 mAb cocktail and Lilly announced that the U.S. government has contracted to...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting nuclear accumulation of IL-33 could treat glioblastoma multiforme by reducing recruitment of pro-tumorigenic innate immune cells to the tumor microenvironment. In patients with glioblastoma multiforme, high expression of...
BioCentury | Oct 28, 2020
Deals

In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

Through its latest deal with CStone, EQRx is looking to bring lower cost PD-1 and PD-L1 inhibitors to market. EQRx Inc. launched in January with a $200 million series A and a mission to bring innovative...
BioCentury | Oct 28, 2020
Product Development

Angelman trial pause for antisense oligo comes with efficacy data that lift Ultragenyx shares

GeneTx and Ultragenyx will look to adjust dosing and administration in their Phase I/II trial of GTX-102 to treat Angelman syndrome after patients experienced a serious adverse event thought...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitorApellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the...
BioCentury | Oct 28, 2020
Product Development

Oct. 27 Quick Takes: NIH ends enrollment COVID-19 trial of Lilly’s bamlanivimab; plus Amgen, Kala

NIH trial of Lilly-AbCellera COVID-19 mAb stopped for futilityNIH has ended enrollment in the ACTIV-3 trial of bamlanivimab to treat hospitalized COVID-19 patients due to lack of efficacy when combined with Veklury remdesivir from Gilead Sciences...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the agency was unable to inspect Hanmi Bioplant, the drug substance...
Items per page:
1 - 10 of 65186
BioCentury | Oct 29, 2020
Product Development

Vowing transparency at interim COVID-19 vaccine readout, Moderna expects ‘dialogue’ with FDA about unblinding study

Contrasting comments from Pfizer management on Tuesday, Moderna promised full transparency with regard to interim results from its Phase III COVE study of COVID-19 vaccine mRNA-1273. The company pledged to report either a positive or...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

A $310 million crossover round will enable Chinese in-licensing play LianBio to “cast a wide net” as it looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury. Perceptive Advisors seeded,...
BioCentury | Oct 28, 2020
Deals

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

With $56 million in fresh funding from a crossover syndicate, newly launched Longboard will develop three neuroscience programs spun out from Arena that share familiar targets with therapies previously developed by the parent company. The...
BioCentury | Oct 28, 2020
Deals

Supply constraints loom as Regeneron reports positive data on COVID-19 mAb

Days before FDA is expected to decide about their emergency use authorization requests, Regeneron released new data confirming the efficacy of its COVID-19 mAb cocktail and Lilly announced that the U.S. government has contracted to...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting nuclear accumulation of IL-33 could treat glioblastoma multiforme by reducing recruitment of pro-tumorigenic innate immune cells to the tumor microenvironment. In patients with glioblastoma multiforme, high expression of...
BioCentury | Oct 28, 2020
Deals

In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

Through its latest deal with CStone, EQRx is looking to bring lower cost PD-1 and PD-L1 inhibitors to market. EQRx Inc. launched in January with a $200 million series A and a mission to bring innovative...
BioCentury | Oct 28, 2020
Product Development

Angelman trial pause for antisense oligo comes with efficacy data that lift Ultragenyx shares

GeneTx and Ultragenyx will look to adjust dosing and administration in their Phase I/II trial of GTX-102 to treat Angelman syndrome after patients experienced a serious adverse event thought...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitorApellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the...
BioCentury | Oct 28, 2020
Product Development

Oct. 27 Quick Takes: NIH ends enrollment COVID-19 trial of Lilly’s bamlanivimab; plus Amgen, Kala

NIH trial of Lilly-AbCellera COVID-19 mAb stopped for futilityNIH has ended enrollment in the ACTIV-3 trial of bamlanivimab to treat hospitalized COVID-19 patients due to lack of efficacy when combined with Veklury remdesivir from Gilead Sciences...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the agency was unable to inspect Hanmi Bioplant, the drug substance...
Items per page:
1 - 10 of 65186